Ticker > Company >

Piramal Pharma share price

Piramal Pharma Ltd.

NSE: PPLPHARMA BSE: 543635 SECTOR: Pharmaceuticals & Drugs  1.52 L   253   79

183.60
0 0
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 188.05

Today's Low

₹ 182.8

52 Week High

₹ 307.85

52 Week Low

₹ 180.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

24405 Cr.

Enterprise Value

25449.09 Cr.

No. of Shares

132.92 Cr.

P/E

33.93

P/B

3.25

Face Value

₹ 10

Div. Yield

0.08 %

Book Value (TTM)

₹  56.48

CASH

177.84 Cr.

DEBT

1221.93 Cr.

Promoter Holding

34.86 %

EPS (TTM)

₹  5.41

Sales Growth

20.4%

ROE

9.83 %

ROCE

12.4%

Profit Growth

76.73 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 23Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year20.4%
3 Year16.53%
5 YearNA

Profit Growth

1 Year76.73%
3 Year23.45%
5 YearNA

ROE%

1 Year9.83%
3 Year5.9%
5 Year7.92%

ROCE %

1 Year12.4%
3 Year8.13%
5 Year10.09%

Debt/Equity

0.1654

Price to Cash Flow

44.47

Interest Cover Ratio

8.9534

CFO/PAT (5 Yr. Avg.)

0.603727117963236

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 34.86 0.00
Mar 2025 34.95 0.00
Dec 2024 34.95 0.00
Sep 2024 34.95 0.00
Jun 2024 34.95 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 23.4454028821182% for the Past 3 years.
  • The company has shown a good revenue growth of 16.5288394561849% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 8.9534.
  • Company’s PEG ratio is 0.443281834947129.
  • The company has an efficient Cash Conversion Cycle of -6.73699999999999 days.

 Limitations

  • Company has a poor ROE of 5.90453333333333% over the past 3 years.
  • The company is trading at a high PE of 33.93.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 1063.2 1284.39 1248.32 1689.8 969.88
Total Expenditure 911.57 1031.5 1028.98 1273.22 925.55
Operating Profit 151.63 252.89 219.34 416.58 44.33
Other Income 36.76 106.38 24.7 39.51 180.92
Interest 24.88 29.95 29.17 30.56 23.23
Depreciation 51.85 53.61 55.46 61.17 59.44
Exceptional Items 0 0 0 0 0
Profit Before Tax 111.66 275.71 159.41 364.36 142.58
Tax 26.39 65.65 40.61 87.09 29.44
Profit After Tax 85.27 210.06 118.8 277.27 113.14
Adjusted EPS (Rs) 0.64 1.59 0.9 2.09 0.85

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 2938.81 3340.42 3443.22 4390.11 5285.71
Total Expenditure 2319.88 2865.14 3345.69 3790.71 4276.55
Operating Profit 618.93 475.28 97.53 599.4 1009.16
Other Income 197.97 224.79 341.07 220.58 238.63
Interest 4.71 57.29 115.87 107.1 114.56
Depreciation 143.64 165.37 192.08 205.26 222.09
Exceptional Items 18.23 -15.08 -6.96 0 0
Profit Before Tax 686.78 462.33 123.69 507.62 911.14
Tax 115.28 94.79 54.19 116.4 219.74
Net Profit 571.5 367.54 69.5 391.22 691.4
Adjusted EPS (Rs.) 5.61 3.03 0.57 2.96 5.22

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 994.6 1185.91 1193.32 1322.95 1324.35
Total Reserves 3106.02 3937.21 4068.47 5389.12 6128.19
Borrowings 0 477.12 592.34 363.94 356.84
Other N/C liabilities 184.38 323.6 490.83 495.86 842.5
Current liabilities 1566.96 1655.39 1951.29 2307.35 2306.49
Total Liabilities 5851.96 7579.23 8296.25 9879.22 10958.37
Assets
Net Block 1626.81 2438.98 2601.87 2612.16 2894.28
Capital WIP 79.34 157.47 136.5 232.4 77.68
Intangible WIP 41.66 247.69 280.07 300.84 249.62
Investments 1591.52 1592.52 1646.87 1646.88 3105.31
Loans & Advances 649.84 963.54 1282.22 1715.86 1095.6
Other N/C Assets 0 0.04 0.04 0 0
Current Assets 1862.79 2178.99 2348.68 3371.08 3535.88
Total Assets 5851.96 7579.23 8296.25 9879.22 10958.37
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 668.55 477.41 123.69 507.62 911.14
Adjustment -310.48 42.92 50.7 221.26 264.51
Changes in Assets & Liabilities -228.06 -168.48 -42.84 -292.78 -392.59
Tax Paid -95.29 -102.66 -60.03 -77.81 -234.29
Operating Cash Flow 34.72 249.19 71.52 358.29 548.77
Investing Cash Flow -4382.89 -1164.62 -435.05 -635.15 -551.96
Financing Cash Flow 4494.16 896.4 290.12 451.38 -61.74
Net Cash Flow 145.99 -19.03 -73.41 174.52 -64.93

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 34.95 34.95 34.95 34.95 34.86
anand piramal trust 0.05 0.05 0.05 0.05 0.05
master dev piramal deyoun... 0.01 0.01 0.01 0.01 0.01
mr. ajay g. piramal 0.04 0.04 0.04 0.04 0.04
mr. anand piramal 0.07 0.07 0.07 0.07 0.07
mr. peter deyoung 0.03 0.03 0.03 0.03 0.03
ms. anya piramal deyoung 0.01 0.01 0.01 0.01 0.01
ms. nandini piramal 0.02 0.02 0.02 0.02 0.02
nandini piramal trust 0.04 0.04 0.04 0.04 0.04
piramal welfare trust (fo... 0.80 0.80 0.80 0.80 0.80
prl realtors llp 3.00 3.00 3.00 3.00 2.99
semplice corporate soluti... - - - 0.67 0.67
the ajay g. piramal found... 0.33 0.33 0.33 0.33 0.33
the sri krishna trust thr... 26.62 26.62 26.62 26.62 26.55
v3 designs llp 3.25 3.25 3.25 3.25 3.24
aasan corporate solutions... 0.67 0.67 0.67 - -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 65.05 65.05 65.05 65.05 65.14
ca alchemy investments 18.00 18.00 18.00 18.00 17.95
canara robeco mutual fund... - - - 1.21 1.12
east bridge capital maste... 4.35 3.27 2.65 2.61 2.23
hdfc trustee company limi... 6.66 7.13 7.39 8.27 9.03
indiahold limited 1.30 1.30 1.30 1.30 1.30
investor education and pr... 0.24 0.24 0.24 0.24 0.24
llp 0.87 0.80 0.71 0.47 0.46
life insurance corporatio... 1.84 1.62 1.36 - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
Research Ventura
Research Edelweiss
Research Nuvama Wealth
Research NuvamaWealth
Research Nuvama Wealth

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY24
Concall Q2FY24
Concall Q1FY25
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY23
Presentation Q3FY25
Presentation Q3FY24
Presentation Q2FY24
Presentation Q1FY25
Presentation Q1FY24

Company News

Piramal Pharma Solutions, NewAmsterdam Pharma open OSD form suite at Sellersville facility 22 Aug, 10:51 AM Piramal Pharma informs about transcript of conference call 31 Jul, 5:28 PM Piramal Pharma reports consolidated net loss of Rs 81.70 crore in Q1 29 Jul, 12:30 PM Piramal Pharma - Quaterly Results 28 Jul, 9:59 PM Piramal Pharma - Quaterly Results 28 Jul, 9:59 PM Piramal Pharma informs about updates 10 Jul, 3:18 PM USFDA concludes GMP inspection at Piramal Pharma’s Canada facility 2 Jun, 3:14 PM Piramal Pharma informs about disclosure 2 Jun, 1:04 PM Piramal Pharma informs about outcome of allotment committee meet 21 May, 4:14 PM Piramal Pharma reports 51.57% rise in Q4 consolidated net profit 15 May, 12:30 PM Piramal Pharma - Quaterly Results 14 May, 8:49 PM Piramal Pharma - Quaterly Results 14 May, 8:49 PM Piramal Pharma receives EIR from USFDA for Turbhe facility 12 May, 12:12 PM Piramal Pharma informs about conference call 29 Apr, 5:27 PM Piramal Pharma’s arm inks pact with PPL Pharma 24 Apr, 12:38 PM Piramal Finance partners with ICICI Bank 10 Apr, 3:22 PM Piramal Pharma commences commercial production of Sevoflurane at Telangana facility 2 Apr, 5:51 PM Piramal Pharma’s arm, BPCO get UKMHRA approval for Neoatricon in UK 21 Mar, 10:46 AM USFDA concludes General GMP inspection at Turbhe facility of Piramal Pharma 19 Feb, 10:21 AM Piramal Pharma informs about updates 31 Jan, 12:58 PM Piramal Pharma - Quaterly Results 28 Jan, 8:46 PM Piramal Pharma - Quaterly Results 28 Jan, 8:46 PM Piramal Pharma’s division launches Chlorpromazine Hydrochloride for Injection, USP 23 Jan, 9:44 AM Piramal Pharma reports over 4-fold jump in Q2 consolidated net profit 24 Oct, 11:30 AM Piramal Pharma - Quaterly Results 23 Oct, 8:07 PM Piramal Pharma - Quaterly Results 23 Oct, 8:07 PM Piramal Pharma’s PPS business to invest $80 million to expand Kentucky facility 1 Oct, 11:58 AM Piramal Pharma gets SBTi approval for GHG Commitment 17 Sep, 10:57 AM Piramal Pharma informs about disclosure 10 Sep, 5:36 PM Piramal Pharma to subscribe preference shares in arm against outstanding loan 30 Aug, 11:44 AM Piramal Pharma informs about disclosure 31 Jul, 2:51 PM Piramal Pharma gets nod to sell unit in Thane 31 Jul, 2:11 PM Piramal Pharma reports consolidated net loss of Rs 88.64 crore in Q1 27 Jul, 3:00 PM Piramal Pharma - Quaterly Results 26 Jul, 12:41 PM Piramal Pharma - Quaterly Results 26 Jul, 12:41 PM Piramal Pharma - Quaterly Results 26 Jul, 12:41 PM Piramal Pharma informs about grant of stock options 26 Jul, 11:04 AM USFDA completes inspection at Piramal Pharma’s PPDS Ahmedabad facility 13 Jul, 11:01 AM Piramal Pharma submits BRSR 2 Jul, 5:31 PM Piramal Pharma informs about AGM and annual report 2 Jul, 5:19 PM Piramal Pharma informs about analyst meet 4 Jun, 4:51 PM Piramal Pharma informs about disclosures 31 May, 5:20 PM Piramal Pharma informs about disclosure 23 May, 11:36 AM Piramal Pharma reports 2- fold jump in Q4 consolidated net profit 13 May, 11:41 AM Piramal Pharma - Quaterly Results 10 May, 8:31 PM Piramal Pharma - Quaterly Results 10 May, 8:31 PM Piramal Pharma’s consumer products division launches new digital campaign for 'Polycrol’ 7 May, 4:12 PM Piramal Pharma informs about disclosure 27 Apr, 2:48 PM Piramal Pharma’s consumer products division forays into men's grooming segment 11 Apr, 4:31 PM Piramal Pharma informs about disclosure 18 Mar, 3:18 PM

Piramal Pharma Stock Price Analysis and Quick Research Report. Is Piramal Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Piramal Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Piramal Pharma has a PE ratio of 33.9006856276912 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Piramal Pharma has ROA of 6.6361% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Piramal Pharma has a Current ratio of 1.533.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Piramal Pharma has a ROE of 9.8255%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Piramal Pharma has a Debt to Equity ratio of 0.1654 which means that the company has low proportion of debt in its capital.

  • Sales growth: Piramal Pharma has reported revenue growth of 20.4004% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Piramal Pharma for the current financial year is 19.0922316964041%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Piramal Pharma is Rs 0.14 and the yield is 0.0763%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Piramal Pharma is Rs 5.4111. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Piramal Pharma in Ticker for free. Also, one can get the intrinsic value of Piramal Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Piramal Pharma FAQs

Q1. What is Piramal Pharma share price today?
Ans: The current share price of Piramal Pharma is Rs 183.44.

Q2. What is the market capitalisation of Piramal Pharma?
Ans: Piramal Pharma has a market capitalisation of Rs 24383.72769672 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Piramal Pharma?
Ans: The PE ratio of Piramal Pharma is 33.9006856276912 and the P/B ratio of Piramal Pharma is 3.24812264389817, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Piramal Pharma share?
Ans: The 52-week high share price of Piramal Pharma is Rs 307.9, and the 52-week low share price of Piramal Pharma is Rs 181.73.

Q5. Does Piramal Pharma pay dividends?
Ans: Currently, Piramal Pharma pays dividends. Dividend yield of Piramal Pharma is around 0.0763%.

Q6. What are the face value and book value of Piramal Pharma shares?
Ans: The face value of Piramal Pharma shares is Rs 10, while the book value per share of Piramal Pharma is around Rs 56.4757. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Piramal Pharma?
Ans: Piramal Pharma has a total debt of Rs 1221.93 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Piramal Pharma?
Ans: The ROE of Piramal Pharma is 9.8255% and ROCE of Piramal Pharma is 12.4038%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Piramal Pharma a good buy for the long term?
Ans: The Piramal Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Piramal Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Piramal Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Piramal Pharma’s financials?
Ans: You can review Piramal Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Piramal Pharma
X